

sCD163 increase in HIV/CMV coinfectd subjects included in ICONA Cohort

Serena Vita¹, Miriam Lichtner², Giulia Marchetti³, Claudia Mascia¹, Esther Merlini³, Paola Cicconi³, Vincenzo Vullo¹, Pier Luigi Viale⁴, Alberto Costantini⁵, Antonella d'Arminio Monforte² for ICONA Foundation Study Group

Serena Vita, MD PhD
 University of Rome Sapienza
 Viale del Policlinico, 133
 00185 Rome, Italy
 E-mail: serena.vita@gmail.com



¹University of Rome Sapienza, Rome, Italy, ²University of Rome Sapienza, Polo Pontino, Latina, Italy, ³San Paolo Hospital, Milano, Italy, ⁴University of Ancona, Ancona, Italy, ⁵University of Bologna, Bologna, Italy.

Background

Accumulating evidence suggest that inflammatory cytokines produced by monocytes/macrophages play a role in the vascular disease and cognitive decline. In HIV patients, herpes virus coinfection has been proposed as a key factor in sustaining immune activation, even in presence of HIV plasma viral control. In our previous study on the ICONA cohort we showed that in HIV patients (pts), CMV infection is an independent risk factor for non AIDS events/deaths (fig. 1).




Fig. 1 shows the increased rate of incurring in SNA event/NA death. Lichtner et al., 2014.

Aims

- To study the differences in plasma markers of myeloid immune activation, related to cardio-cerebro vascular diseases in HIV monoinfected and HIV/CMV coinfectd pts,
- To correlate CMV IgG levels in HIV/CMV+ with soluble activation markers.

Study population

Screening of all the ICONA patients with an available CMV serology at enrolment (or within 6 months) and a plasma sample after ≥ 1 year of successful ART (defined as an undetectable HIV viral load and CD4+ count more than 200/mc).

Matching criteria	HIV/CMV- (23 pts)	HIV/CMV+ (46 pts)
Sex	2F, 21M	4F, 42M
Age (Mdn, min-max)	40 (34-52)	42 (31-54)
CD4 nadir (mm ³ , Mdn, min-max)	281 (2-598)	207 (2-611)
HBV	0	0
HCV	7	14

Tab. 1 shows the matching criteria of the 2 groups.

Among these patients 2 different groups have been constituted: CMV-infected and CMV-uninfected patients. CMV chronic infection was defined on CMV IgG presence.

We selected HIV CMV+ and CMV- patients with a plasma sample after 1 year or more of successful therapy, matched for sex, age, CD4 nadir, HBV and HCV (see table 1).

Exclusion criteria

Previous or current CMV organ diseases, organ transplantation, use of immunosuppressive or immunomodulant drugs in the last year, cancer or treatment for cancer in the previous 5 years, insulin dependent diabetes mellitus, glomerular filtration rate < 39 ml/min, severe liver disease, endocrine disorders, autoimmune disease.

Materials and methods

Immunological Assays

Plasma levels in duplicate of :

IL-6 and TNF α : (pg/ml) eBIOSCENCE, sCD163 and sCD14(ng/ml) R&D Systems

CMV ELISA Quantitation Kit: GenWay Biotech used to retest all samples and in the CMV positive populations to quantify Ab levels in duplicate.

Statistical analysis

Mann-Whitney Test, Spearman correlation analysis (Prima 6.0 software)

Results

A total of 69 subjects were recruited, 46 HIV monoinfected (CMV-) and 23 HIV/CMV (CMV+) coinfectd.

A higher median of sCD163 level (927.7 vs. 497.8 ng/ml, p=0.018) was found in CMV+ compared to CMV- group (fig.2 A). TNF α , sCD14 were also elevated but did not reach a significant difference in comparison to HIV/CMV- subjects (fig. 3).

In HIV/CMV+ subjects a significant correlation was shown between anti-CMV IgG levels and sCD163 (r=0.49, p=0.006) (fig.2 B). Moreover only in CMV+ subjects sCD163 levels were related to the duration of HIV infection (r=0.29, p=0.04). In the CMV positive group comparing CMV IgG levels with CD4 count, at the time of sampling, we found a significant negative correlation (r=0.39, p=0.0006).




Fig. 3 shows TNF α and sCD14 levels in HIV/CMV- vs. HIV/CMV+.






Fig. 2A shows sCD163 levels in HIV/CMV- vs. HIV/CMV+. 2B shows correlation between CMV IgG levels with sCD163.

Conclusions

CMV chronic infection appears to be linked to an increase in sCD163, a markers of myeloid activation, in HIV infected subjects under successful ART with controlled biological (age and sex) and HIV related (HIV suppression, CD4 nadir and CD4 recovery) factors. The persistent activation of monocytes and macrophages that has been implicated in the accelerated development of vascular and neurological disease in general population, may explain the increased risk of non AIDS events found in HIV/CMV coinfectd subjects.



Board of Directors: M. Moroni (Chair), M. Andreoni, G. Angarano, A. Antinori, A. d'Arminio Monforte, F. Castelli, R. Cauda, G. Di Perri, M. Galli, R. Iardino, G. Ippolito, A. Lazzarin, C.F. Perno, F. von Schöller, P.L. Viale
Presidential: A. Cozzi-Lepri, P. Cicconi, I. Fanti, T. Formenti, L. Galli, P. Lorenzini
Biological Bank INMI: F. Carletti, S. Carrara, A. Castrogiovanni, A. Di Caro, F. Petrone, G. Prota, S. Quartu
Participating Physicians and Centers:
Ancona - A. Giacometti, S. Mazzocato, E. Orsetti; **Bari** - G. Angarano, L. Monno, C. Santoro; **Bergamo** - F. Maggiolo, C. Suardi; **Bologna** - M. Borderi, V. Donati, E. Vanino, G. Verucchi, P. Viale; **Brescia** - F. Castelli, C. Minardi, E. Quiros Roldan; **Busto Arsizio** - C. Abelli, T. Quirino; **Catania** - G. Nunnari, B. Celesia; **Chieti** - K. Falasca, J. Vecchetti; **Ferrara** - D. Segala, L. Sighinolfi; **Firenze** - F. Mazzotta, S. Lo Caputo; **Genova** - A.I. Alessandrini, N. Bobbio, G. Cassola, G. Mazzarello, R. Piscopo, C. Viscoli; **Lecco** - P. Bonfanti, I. Caramma; **Macerata** - P. Castelli, A. Chiodera; **Milano** - L. Carezzi, A. Castagna, P. Cicconi, A. d'Arminio Monforte, M. Galli, A. Lazzarin, G. Marchetti, M.C. Moio, R. Piolini, M. Puoti, A. Ridolfo, G. Rizzardini, S. Salpietro; **Modena** - C. Mussini, C. Puziolante
Monza - A. Gori, G. Lapadula; **Napoli** - N. Abrescia, A. Chiriami, M. Gargiulo, A. Maddaloni; **Perugia** - F. Baldelli, D. Francisci; **Pescara** - G. Parruti, T. Ursini; **Reggio Emilia** - G. Magnani, M. Ursitti; **Roma** - R. Acinapura, A. Ammassari, M. Andreoni, A. Antinori, M. Capozzi, R. Cauda, A. Cingolani, A. d'Avino, A. De Luca, L. Gallo, R. Libertone, C. Mastroianni, E. Nicastrì, G. Tebano, V. Vullo; **Rovigo** - A.M. Cattelan; **Sassari** - G. Madeddu, P.E. Manconi, M.S. Mura, P. Piano; **Sienna** - A. De Luca, B. Rossetti; **Siracusa** - R. Fontana Del Vecchio, A. Franco; **Torino** - S. Bonora, P. Caramello, G. Di Perri, G. Orofino, M. Sciarda; **Udine** - M. Bassetti, A. Londero; **Vicenza** - V. Manfrin, G. Pellizzer; **Committee:** A. Antinori, A. d'Arminio Monforte, A. Lazzarin, M. Moroni, G. Ippolito, C.F. Perno
Scientific Secretary: A. d'Arminio Monforte (Coordinator), A. Antinori, A. Castagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, E. Girardi, S. Lo Caputo, C. Mussini, M. Puoti
Scientific Committee: A. Ammassari, M. Andreoni, A. Antinori, A. d'Arminio Monforte, C. Balotta, P. Bonfanti, S. Bonora, M. Borderi, M.R. Capobianchi, A. Castagna, F. Ceccherini-Silberstein, A. Cingolani, P. Cinque, A. Cozzi-Lepri, A. De Luca, A. Di Biagio, N. Gianotti, E. Girardi, A. Gori, G. Guaraldi, G. Lapadula, M. Lichtner, S. Lo Caputo, G. Madeddu, F. Maggiolo, G. Marchetti, S. Marcotullio, L. Monno, C. Mussini, M. Puoti, E. Quiros Roldan, S. Rusconi
Statistical and Monitoring Team: